Table 1 Study cohort’s characteristics
From: Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer
Development cohort (N = 413) | Validation cohort (N = 310) | ||||
|---|---|---|---|---|---|
N | (%) | N | (%) | P-value | |
HER2 status | 0.695 | ||||
Negative | 343 | (83.1) | 254 | (81.9) | |
Positive | 70 | (16.9) | 56 | (18.1) | |
Gender | 0.237 | ||||
Male | 262 | (63.4) | 210 | (67.7) | |
Female | 151 | (36.6) | 100 | (32.3) | |
Type of material | <0.001a | ||||
<6 biopsies | 99 | (24) | 77 | (24.8) | |
≥6 biopsies | 24 | (5.8) | 82 | (26.5) | |
Surgical sample | 287 | (69.5) | 151 | (48.7) | |
Not specified | 3 | (0.7) | 0 | (0) | |
Site of sampling | 0.077 | ||||
Primary tumour | 365 | (88.4) | 287 | (92.6) | |
Metastases | 48 | (11.6) | 23 | (7.4) | |
Primary tumour location | <0.001a | ||||
O-G junction | 118 | (28.6) | 73 | (23.5) | |
Body | 261 | (63.2) | 160 | (51.6) | |
Fundus | 21 | (5.1) | 52 | (16.8) | |
Not specified | 13 | (3.1) | 25 | (8.1) | |
Lauren’s histotype | 0.559a | ||||
Intestinal | 193 | (46.7) | 103 | (33.2) | |
Diffuse | 183 | (44.3) | 108 | (34.8) | |
Not specified | 37 | (9) | 99 | (32) | |
Tumour grading | 0.343a | ||||
G1 | 10 | (2.4) | 11 | (3.5) | |
G2 | 100 | (24.2) | 56 | (18.1) | |
G3 | 289 | (70) | 178 | (57.4) | |
Not specified | 14 | (3.2) | 65 | (21) | |
